Facebook Tracking Image

National Comprehensive Cancer Network

Members Only
NCCN Oncology Research Program (ORP)
NCCN Taiho Decitabine and Cedazuridine Research Grant Opportunity: Submit by Tuesday, January 19, 2021
Study Proposal Submission-NCCN iEnvision
ORP Recent News
ORP Scientific Publications
ORP for Industry
ORP Investigator Steering Committee
ORP Testimonials
Clinical Trials at NCCN Member Institutions
Find NCCN ORP Funded Clinical Trials at NCCN Member Institutions
ORP Grant History
Informed Consent Language Database
Points to Consider on the Best Practices for Biorepositories, Registries and Databases
NCCN Shared Resources
ORP Disclosure Policy
NCCN Collaboration with the National Business Group on Health
NCCN Health Information Technology Licensees
NCCN Policy Priorities

NCCN Research & Business Resources

NCCN Oncology Research Program (ORP) Testimonials

Our success in bringing much needed funding to investigators at NCCN Member Institutions for important research is evidenced by testimonials from some of our distinguished investigators and industry collaborators.

“The NCCN Oncology Research Program added valuable collaborative networking to Spectrum’s (Allos) Investigator-Initiated Study program. The RFPs identified capable investigators offering several opportunities we may have otherwise missed. This program is administered with great professionalism and is an asset to post-marketing development goals.”
Mark Acosta, PharmD
Spectrum Pharmaceuticals

“Pfizer’s independent grant programs with the NCCN ORP continue to be successful. NCCN is a credible and trusted organization committed to driving the highest standards in science and medicine. The professional staff are experienced in working with a wide network of oncology health care professionals and they demonstrate great attention-to-detail in the efficient execution of our grant award projects. It is a pleasure and a privilege to be able to work together.”
Jacqueline Waldrop
Pfizer, Inc.

“There is an urgent need for patients to be able to access novel agents through innovative clinical trials in the cancer field. The Oncology Research Program of the National Comprehensive Cancer Network comprises a unique program that provides clinical researchers the ability to conduct pioneering, investigator-designed studies with cutting-edge anti-cancer drugs.”
Razelle Kurzrock, MD
UC San Diego - Moores Cancer Center

“Kudos to the ORP of the NCCN as it is very important to investigators from NCCN Member Institutions. It allows them to compete for grants from industry who support the program for investigator initiated studies at a time when funds are scarce.”
David S. Ettinger, MD, FACP, FCCP
The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins

“The NCCN Oncology Research Program is an excellent opportunity to obtain funding for clinical trials with novel therapeutic agents. The support provided by NCCN is invaluable, allowing investigators to complete and publish studies timely.”
Frank Worden, MD
University of Michigan Comprehensive Cancer Center

“The NCCN ORP is an invaluable resource for peer-reviewed funding for academic investigators, especially those in early phases of their careers. The rigorous scientific review of the proposal by experts in the field enhances the final product, be it a clinical trial or laboratory-based research. As a recipient of these prestigious grants, I can attest that this is a win-win for all involved; the sponsor, the grantor, and the recipient.”
Nikhil I. Khushalani, MD
Moffitt Cancer Center